Skip to main content

Carbimazole‐induced agranulocytosis: does antineutrophil cytoplasmic antibody have a role?

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs.

Keywords: Graves' disease; agranulocytosis; antineutrophil cytoplasmic antibody; autoantibody; carbimazole; pyoderma gangrenosum

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1445-5994.2009.02143.x

Affiliations: 1: Department of Medicine 2: Endocrine Centre and 3: Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Victoria, Australia

Publication date: 2010-04-01

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more